Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.5% during the third quarter, HoldingsChannel.com reports. The fund owned 248,636 shares of the company’s stock after selling 11,842 shares during the period. Principal Financial Group Inc.’s holdings in Prestige Consumer Healthcare were worth $17,927,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Prestige Consumer Healthcare in the second quarter valued at $550,000. Sequoia Financial Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 12.9% during the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after acquiring an additional 1,120 shares during the period. Barclays PLC grew its position in shares of Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after acquiring an additional 71,730 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its holdings in shares of Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock worth $1,776,000 after acquiring an additional 9,269 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Up 0.6 %

PBH opened at $79.23 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market capitalization of $3.91 billion, a PE ratio of 19.28, a P/E/G ratio of 2.32 and a beta of 0.49. The stock’s fifty day moving average is $79.71 and its 200-day moving average is $73.39. Prestige Consumer Healthcare Inc. has a one year low of $57.95 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the previous year, the business earned $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on PBH shares. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $85.25.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the sale, the senior vice president now owns 18,835 shares of the company’s stock, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.